{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:01:55Z","timestamp":1766023315257,"version":"3.48.0"},"reference-count":32,"publisher":"e-Century Publishing Corporation","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/gcge6470","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:52:52Z","timestamp":1753941172000},"page":"3197-3208","source":"Crossref","is-referenced-by-count":0,"title":["Short- and long-term efficacy of olaparib combined with chemotherapy in advanced triple-negative breast cancer"],"prefix":"10.62347","volume":"15","author":[{"given":"Wanfu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S and Chen Y. Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 2022; 15: 121.","journal-title":"J Hematol Oncol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","unstructured":"Yin L, Duan JJ, Bian XW and Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 2020; 22: 61.","journal-title":"Breast Cancer Res"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ and Shao ZM. Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab 2023; 35: 84-100, e108.","DOI":"10.1016\/j.cmet.2022.09.021"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Shiao SL, Gouin KH 3rd, Ing N, Ho A, Basho R, Shah A, Mebane RH, Zitser D, Martinez A, Mevises NY, Ben-Cheikh B, Henson R, Mita M, McAndrew P, Karlan S, Giuliano A, Chung A, Amersi F, Dang C, Richardson H, Shon W, Dadmanesh F, Burnison M, Mirhadi A, Zumsteg ZS, Choi R, Davis M, Lee J, Rollins D, Martin C, Khameneh NH, McArthur H and Knott SRV. Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancer. Cancer Cell 2024; 42: 70-84, e78.","DOI":"10.1016\/j.ccell.2023.12.012"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer - expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L and Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol 2022; 19: 91-113.","journal-title":"Nat Rev Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/14737140.2021.1840984","article-title":"Triple-negative breast cancer: promising prognostic biomarkers currently in development","volume":"21","author":"Sukumar","year":"2021","unstructured":"Sukumar J, Gast K, Quiroga D, Lustberg M and Williams N. Triple-negative breast cancer: promising prognostic biomarkers currently in development. Expert Rev Anticancer Ther 2021; 21: 135-148.","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","article-title":"Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies","volume":"212","author":"Karim","year":"2023","unstructured":"Karim AM, Eun Kwon J, Ali T, Jang J, Ullah I, Lee YG, Park DW, Park J, Jeang JW and Kang SC. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem Pharmacol 2023; 212: 115545.","journal-title":"Biochem Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3390\/ijms24032969","article-title":"Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review","volume":"24","author":"van den Ende","year":"2023","unstructured":"van den Ende NS, Nguyen AH, Jager A, Kok M, Debets R and van Deurzen CHM. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: a systematic review. Int J Mol Sci 2023; 24: 2969.","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"106936","DOI":"10.1016\/j.ijsu.2022.106936","article-title":"Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery","volume":"107","author":"Zou","year":"2022","unstructured":"Zou Y, Xie J, Zheng S, Liu W, Tang Y, Tian W, Deng X, Wu L, Zhang Y, Wong CW, Tan D, Liu Q and Xie X. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg 2022; 107: 106936.","journal-title":"Int J Surg"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","unstructured":"Asleh K, Riaz N and Nielsen TO. Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications. J Exp Clin Cancer Res 2022; 41: 265.","journal-title":"J Exp Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"14937","DOI":"10.3390\/ijms232314937","article-title":"Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer","volume":"23","author":"Kudelova","year":"2022","unstructured":"Kudelova E, Smolar M, Holubekova V, Hornakova A, Dvorska D, Lucansky V, Koklesova L, Kudela E and Kubatka P. Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer. Int J Mol Sci 2022; 23: 14937.","journal-title":"Int J Mol Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.3390\/curroncol29070378","article-title":"Triple-negative breast cancer: a review of current curative intent therapies","volume":"29","author":"MacDonald","year":"2022","unstructured":"MacDonald I, Nixon NA and Khan OF. Triple-negative breast cancer: a review of current curative intent therapies. Curr Oncol 2022; 29: 4768-4778.","journal-title":"Curr Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jare.2023.02.005","article-title":"A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer","volume":"54","author":"Kumar","year":"2023","unstructured":"Kumar H, Gupta NV, Jain R, Madhunapantula SV, Babu CS, Kesharwani SS, Dey S and Jain V. A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer. J Adv Res 2023; 54: 271-292.","journal-title":"J Adv Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"107205","DOI":"10.1016\/j.phrs.2024.107205","article-title":"Epigenetic modulations in triple-negative breast cancer: therapeutic implications for tumor microenvironment","volume":"204","author":"Zhou","year":"2024","unstructured":"Zhou L and Yu CW. Epigenetic modulations in triple-negative breast cancer: therapeutic implications for tumor microenvironment. Pharmacol Res 2024; 204: 107205.","journal-title":"Pharmacol Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.2217\/fon-2021-1647","article-title":"KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer","volume":"18","author":"Rizzo","year":"2022","unstructured":"Rizzo A, Cusmai A, Acquafredda S, Giovannelli F, Rinaldi L, Misino A and Palmiotti G. KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. Future Oncol 2022; 18: 2301-2309.","journal-title":"Future Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.2147\/IJN.S388075","article-title":"Nanoparticles for chemoimmunotherapy against triple-negative breast cancer","volume":"17","author":"Liu","year":"2022","unstructured":"Liu S, Li J, Gu L, Wu K and Xing H. Nanoparticles for chemoimmunotherapy against triple-negative breast cancer. Int J Nanomedicine 2022; 17: 5209-5227.","journal-title":"Int J Nanomedicine"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.semcancer.2022.03.008","article-title":"Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications","volume":"86","author":"Mehraj","year":"2022","unstructured":"Mehraj U, Mushtaq U, Mir MA, Saleem A, Macha MA, Lone MN, Hamid A, Zargar MA, Ahmad SM and Wani NA. Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications. Semin Cancer Biol 2022; 86: 769-783.","journal-title":"Semin Cancer Biol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2152\/jmi.68.213","article-title":"Triple-negative breast cancer and basal-like subtype: pathology and targeted therapy","volume":"68","author":"Bando","year":"2021","unstructured":"Bando Y, Kobayashi T, Miyakami Y, Sumida S, Kakimoto T, Saijo Y and Uehara H. Triple-negative breast cancer and basal-like subtype: pathology and targeted therapy. J Med Invest 2021; 68: 213-219.","journal-title":"J Med Invest"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM and Rosen JM. Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. bioRxiv 2023; 2023.09.28.559973.","DOI":"10.1101\/2023.09.28.559973"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1038\/s41598-021-83913-7","article-title":"CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer","volume":"11","author":"Craven","year":"2021","unstructured":"Craven KE, Gokmen-Polar Y and Badve SS. CIBERSORT analysis of TCGA and METABRIC identifies subgroups with better outcomes in triple negative breast cancer. Sci Rep 2021; 11: 4691.","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"114090","DOI":"10.1016\/j.biopha.2022.114090","article-title":"BRCA1 deficiency in triple-negative breast cancer: protein stability as a basis for therapy","volume":"158","author":"Choi","year":"2023","unstructured":"Choi E, Mun GI, Lee J, Lee H, Cho J and Lee YS. BRCA1 deficiency in triple-negative breast cancer: protein stability as a basis for therapy. Biomed Pharmacother 2023; 158: 114090.","journal-title":"Biomed Pharmacother"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14737140.2023.2262760","article-title":"Locoregional recurrence in triple negative breast cancer: past, present, and future","volume":"23","author":"Tran","year":"2023","unstructured":"Tran J, Thaper A, Lopetegui-Lia N and Ali A. Locoregional recurrence in triple negative breast cancer: past, present, and future. Expert Rev Anticancer Ther 2023; 23: 1085-1093.","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/s44321-024-00050-0","article-title":"Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer","volume":"16","author":"Inayatullah","year":"2024","unstructured":"Inayatullah M, Mahesh A, Turnbull AK, Dixon JM, Natrajan R and Tiwari VK. Basal-epithelial subpopulations underlie and predict chemotherapy resistance in triple-negative breast cancer. EMBO Mol Med 2024; 16: 823-853.","journal-title":"EMBO Mol Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"107876","DOI":"10.1016\/j.intimp.2021.107876","article-title":"Immune checkpoint inhibitors for triple-negative breast cancer: from immunological mechanisms to clinical evidence","volume":"98","author":"Farshbafnadi","year":"2021","unstructured":"Farshbafnadi M, Pastaki Khoshbin A and Rezaei N. Immune checkpoint inhibitors for triple-negative breast cancer: from immunological mechanisms to clinical evidence. Int Immunopharmacol 2021; 98: 107876.","journal-title":"Int Immunopharmacol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"101396","DOI":"10.1016\/j.xcrm.2024.101396","article-title":"Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer","volume":"5","author":"Liu","year":"2024","unstructured":"Liu CC, Chen L, Cai YW, Chen YF, Liu YM, Zhou YJ, Shao ZM and Yu KD. Targeting EMSY-mediated methionine metabolism is a potential therapeutic strategy for triple-negative breast cancer. Cell Rep Med 2024; 5: 101396.","journal-title":"Cell Rep Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s13258-020-01014-7","article-title":"Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication","volume":"42","author":"Lee","year":"2020","unstructured":"Lee YM, Oh MH, Go JH, Han K and Choi SY. Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication. Genes Genomics 2020; 42: 1381-1387.","journal-title":"Genes Genomics"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"103700","DOI":"10.1016\/j.esmoop.2024.103700","article-title":"Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology","volume":"9","author":"Mazzeo","year":"2024","unstructured":"Mazzeo R, Sears J, Palmero L, Bolzonello S, Davis AA, Gerratana L and Puglisi F. Liquid biopsy in triple-negative breast cancer: unlocking the potential of precision oncology. ESMO Open 2024; 9: 103700.","journal-title":"ESMO Open"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14737159.2023.2173579","article-title":"Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach","volume":"23","author":"Shoukat","year":"2023","unstructured":"Shoukat I and Mueller CR. Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. Expert Rev Mol Diagn 2023; 23: 41-51.","journal-title":"Expert Rev Mol Diagn"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2174\/1389200223666220608144551","article-title":"Nanotechnological approaches for the treatment of triple-negative breast cancer: a comprehensive review","volume":"23","author":"Guha","year":"2022","unstructured":"Guha L, Bhat IA, Bashir A, Rahman JU and Pottoo FH. Nanotechnological approaches for the treatment of triple-negative breast cancer: a comprehensive review. Curr Drug Metab 2022; 23: 781-799.","journal-title":"Curr Drug Metab"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.2217\/fon-2023-0301","article-title":"Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer","volume":"20","author":"Haiderali","year":"2024","unstructured":"Haiderali A, Huang M, Pan W, Akers KG, Maciel D and Frederickson AM. Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer. Future Oncol 2024; 20: 1587-1600.","journal-title":"Future Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"902378","DOI":"10.3389\/fpubh.2022.902378","article-title":"Triple-negative breast cancer analysis based on metabolic gene classification and immunotherapy","volume":"10","author":"Zhou","year":"2022","unstructured":"Zhou Y, Che Y, Fu Z, Zhang H and Wu H. Triple-negative breast cancer analysis based on metabolic gene classification and immunotherapy. Front Public Health 2022; 10: 902378.","journal-title":"Front Public Health"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/jcmm.17124","article-title":"Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment","volume":"26","author":"Li","year":"2022","unstructured":"Li Y, Kong X, Wang Z and Xuan L. Recent advances of transcriptomics and proteomics in triple-negative breast cancer prognosis assessment. J Cell Mol Med 2022; 26: 1351-1362.","journal-title":"J Cell Mol Med"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/7\/ajcr0165711.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:02Z","timestamp":1766023022000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/7\/ajcr0165711.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/gcge6470","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2025]]}}}